The postprandial state and the risk of atherosclerosis

Diabetic Medicine

Volumn 14, Issue SUPPL. 3, 1997, Pages

  Hanefeld, M ^a   Temelkova Kurktschiev, T ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Acarbose; Atherosclerosis; Postprandial; Risk factors

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; GLIBENCLAMIDE;

ACUTE HEART INFARCTION; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; POSTPRANDIAL STATE; RISK FACTOR; TREATMENT OUTCOME;

ADULT; ARTERIOSCLEROSIS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TRIGLYCERIDES;

EID: 0030806467     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199708)14:3+3.0.CO;2-H     Document Type: Article

References (19)

1. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 123-131.
2. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987; 3: 463-524.
3. Stamler J, Vaccaro O, Neaton J, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16: 434-449.
4. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J, the DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-1583.
5. Hanefeld M, Fischer S, Schmechel H, Rothe G, Schulze J, Dude H, Schwanebeck U, Julius U. Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care 1991; 14: 308-317.
6. Haffner SM, Agil A, Mykkanen L, Stern MP, Jialal I. Plasma oxidizability in subjects with normal glucose tolerance, impaired glucose tolerance, and NIDDM. Diabetes Care 1995; 18: 646-653.
7. Agewall S, Fagerberg B, Attvall S, Wendelhag I, Urbanavicius V, Wikstrand J. Carotid artery wall intima-media thickness is associated with insulin-mediated glucose disposal in men at high and low coronary risk. Stroke 1995; 26: 956-960.
8. Picard S, Talussot C, Serusclat A, Ambrosio N, Berthezene F. Minimally oxidised LDL as estimated by a new method increase in plasma of type 2 diabetic patients with atherosclerosis or nephropathy. Diabetes Metab 1996; 22: 25-30.
9. Schrezenmeir J, Keppler I, Fenselau S, Weber P, Biesalski HK, Probst R, et al. The phenomenon of a high triglyceride response to an oral lipid load in healthy subjects and its link to the Metabolic Syndrome. Ann N Y Acad Sci 1993; 683: 302-314.
10. Schrezenmeir J. Hyperinsulinemia, hyperproinsulinemia and insulin resistance in the metabolic syndrome. Experientia 1996; 52: 426-432.
11. Julius U. Aktuelle Therapie der Dyslipoproteinämie beim Metabolischen Syndrom. In: Hanefeld M, Leonhardt W, eds. Das Metabolische Syndrom. Jena: Gustav Fischer Verlag, 1996: 103-113.
12. Sharrett AR, Chambless LE, Heiss G, Paton CC, Patsch W, for the ARIC Investigators. Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 1995; 15: 2122-2129.
13. Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 1992; 12: 1336-1345.
14. Hanefeld M, Schmechel H, Julius U, Fischer S, Schulze J, Schwanebeck U, Lindner J, Hora C, Dude H and the DIS Group. Five-year incidence of coronary heart disease related to major risk factors and metabolic control in newly diagnosed non-insulin-dependent diabetes. The diabetes intervention study (DIS). Nutr Metab Cardiovasc Dis 1991; 1: 135-140.
15. Reynisdottir S, Eriksson M, Angelin B, Arner P. Impaired activation of adipocyte lipolysis in familial combined hyperlipidemia. J Clin Invest 1995; 95: 2161-2169.
16. Bouchard C, Perusse L. Genetics of causes and manifestations of the metabolic syndrome. In: Crepaldi G, Tiengo A, Manzato E, eds. Diabetes, Obesity and Hyperlipidemia: V. The Plurimetabolic Syndrome. Amsterdam: Elsevier Science Publishers, 1993; 67-74.
17. McGarry JD. What it Minkowski had been ageusic? An alternative angle on diabetes. Science 1992; 258: 766-770.
18. Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, Fucker K. Therapeutic potentials of acarbose as first line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991; 14: 732-737.
19. Holman RRH for the UKPDS Group. UK Prospective Diabetes Study: 3-year update. In: Schwartz CJ, Born GVR, eds. New Horizons in Diabetes Mellitus and Cardiovascular Disease. Current Science, 1995: 183-187.